{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:45:57Z","timestamp":1775155557624,"version":"3.50.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>The implementation of a pediatric desensitization protocol specific to etoposide in an adolescent with Hodgkin lymphoma is described.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Etoposide is part of many chemotherapy regimens used to treat malignancies in children and adults, and it is also part of the backbone of many regimens used in clinical trials. Etoposide is known to produce hypersensitivity reactions during administration. Substitution with etoposide phosphate, which has less potential for hypersensitivity reactions, is used in place of etoposide after severe hypersensitivity reactions. Etoposide desensitization protocols (EDPs) have been reported in adult patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The implementation of an etoposide desensitization protocol for pediatric patients is safe and helpful to prevent the elimination of etoposide from treatment protocols. The use of an EDP allowed the patient to remain on clinical trial and complete the prescribed treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxz311","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T09:12:02Z","timestamp":1581066722000},"page":"277-281","source":"Crossref","is-referenced-by-count":10,"title":["A pediatric desensitization protocol for etoposide"],"prefix":"10.1093","volume":"77","author":[{"given":"Nicole","family":"Martinez","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Valley Children\u2019s Hospital, Cancer and Blood Disorders Center, Madera, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Miyasaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Valley Children\u2019s Hospital, Cancer and Blood Disorders Center, Madera, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy","family":"Roh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Valley Children\u2019s Hospital, Cancer and Blood Disorders Center, Madera, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Koole","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Valley Children\u2019s Hospital, Cancer and Blood Disorders Center, Madera, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen S","family":"Fernandez","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Valley Children\u2019s Hospital, Cancer and Blood Disorders Center, Madera, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"issue":"4","key":"2020020704030267400_CIT0001","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.mcna.2010.03.002","article-title":"The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization","volume":"94","author":"Pagani","year":"2010","journal-title":"Med Clin North Am."},{"issue":"3","key":"2020020704030267400_CIT0002","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1081-1206(10)60078-6","article-title":"Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents","volume":"102","author":"Lee","year":"2009","journal-title":"Ann Allergy Asthma Immunol."},{"key":"2020020704030267400_CIT0003","first-page":"613","article-title":"Hypersensitivity reactions.","volume-title":"The chemotherapy source book","author":"Weiss","year":"1996","edition":"2nd ed."},{"issue":"6","key":"2020020704030267400_CIT0004","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1081-1206(10)61024-1","article-title":"Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions","volume":"95","author":"Coors","year":"2005","journal-title":"Ann Allergy Asthma Immunol."},{"issue":"2","key":"2020020704030267400_CIT0005","doi-asserted-by":"crossref","first-page":"272","DOI":"10.4103\/0019-509X.82903","article-title":"Etoposide? Or polysorbate-80?","volume":"48","author":"Aksahin","year":"2011","journal-title":"Indian J Cancer."},{"issue":"4","key":"2020020704030267400_CIT0006","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1002\/1097-0142(19910215)67:4<1070::AID-CNCR2820670434>3.0.CO;2-X","article-title":"Hypersensitivity reactions to epipodophyllotoxins in children with acute lymphoblastic leukemia","volume":"67","author":"Kellie","year":"1991","journal-title":"Cancer."},{"issue":"3","key":"2020020704030267400_CIT0007","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1159\/000353627","article-title":"Hypersensitivity to etoposide in case of metastatic gestational choriocarcinoma","volume":"6","author":"Lazovi\u0107","year":"2013","journal-title":"Case Rep Oncol."},{"issue":"8","key":"2020020704030267400_CIT0008","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1592\/phco.19.11.989.31566","article-title":"Successful rechallenge with etoposide phosphate after an acute hypersensitivity reaction to etoposide","volume":"19","author":"Bernstein","year":"1999","journal-title":"Pharmacotherapy."},{"issue":"1","key":"2020020704030267400_CIT0009","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.bjc.6600003","article-title":"Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide","volume":"86","author":"Siderov","year":"2002","journal-title":"Br J Cancer."},{"issue":"1","key":"2020020704030267400_CIT0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/1078155207085355","article-title":"Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity","volume":"14","author":"Collier","year":"2008","journal-title":"J Oncol Pharm Pract."},{"key":"2020020704030267400_CIT0011","first-page":"1","article-title":"Etoposide phosphate: what, why, where, and how?","volume":"23","author":"Schacter","year":"1996","journal-title":"Semin Oncol."},{"issue":"3","key":"2020020704030267400_CIT0012","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/pbc.25797","article-title":"Successful treatment with etoposide base after an acute hypersensitivity reaction to etoposide phosphate","volume":"63","author":"Leguay","year":"2016","journal-title":"Pediatr Blood Cancer."},{"issue":"3","key":"2020020704030267400_CIT0013","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/bmt.2016.288","article-title":"Etoposide phosphate hypersensitivity overcome using a desensitisation programme enabling optimal therapy for relapsed Hodgkin lymphoma","volume":"52","author":"Polistena","year":"2017","journal-title":"Bone Marrow Transplant."},{"issue":"26","key":"2020020704030267400_CIT0014","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMp1212468","article-title":"The impact of drug shortages on children with cancer\u2013the example of mechlorethamine","volume":"367","author":"Metzger","year":"2012","journal-title":"N Engl J Med."},{"issue":"2","key":"2020020704030267400_CIT0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1200\/JOP.2014.000380","article-title":"Oncologists\u2019 experiences with drug shortages","volume":"11","author":"Kehl","year":"2015","journal-title":"J Oncol Practice"},{"issue":"2","key":"2020020704030267400_CIT0016","first-page":"72","article-title":"Rapid drug desensitization for hypersensitivity reactions to chemotherapy and monoclonal antibodies in the 21st century","volume":"24","author":"Guitart Castells","year":"2014","journal-title":"J Investig Allergol Clin Immunol."},{"issue":"45","key":"2020020704030267400_CIT0017","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.2174\/1381612822666161025154506","article-title":"Desensitization for drug hypersensitivity to chemotherapy and monoclonal antibodies","volume":"22","author":"Bonamichi-Santos","year":"2016","journal-title":"Curr Pharm Des."},{"issue":"1","key":"2020020704030267400_CIT0018","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaip.2013.08.013","article-title":"Desensitization to chemotherapeutic agents","volume":"2","author":"Lieberman","year":"2014","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"5","key":"2020020704030267400_CIT0019","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jaip.2016.05.015","article-title":"A modified protocol for rapid desensitization to chemotherapy agents","volume":"4","author":"Vidal","year":"2016","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"2","key":"2020020704030267400_CIT0020","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10147-014-0722-2","article-title":"Hypersensitivity to chemotherapeutics: a cross sectional study with 35 desensitisations","volume":"20","author":"Goksel","year":"2015","journal-title":"Int J Clin Oncol."},{"issue":"4","key":"2020020704030267400_CIT0021","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jaip.2014.12.014","article-title":"Successful rapid desensitization to intravenous etoposide using a 14-step protocol","volume":"3","author":"Garcia Escallon","year":"2015","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"4","key":"2020020704030267400_CIT0022","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jaip.2016.03.026","article-title":"Safe and time-saving desensitization protocol to intravenous etoposide","volume":"4","author":"G\u00f3mez-Duque","year":"2016","journal-title":"J Allergy Clin Immunol Pract."},{"key":"2020020704030267400_CIT0023","author":"National Cancer Institute.","year":"2006"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/4\/277\/32366888\/zxz311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/4\/277\/32366888\/zxz311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T09:12:19Z","timestamp":1581066739000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/77\/4\/277\/5728840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,2,7]]},"published-print":{"date-parts":[[2020,2,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxz311","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2,15]]},"published":{"date-parts":[[2020,2,7]]}}}